European Reference Laboratory Network for Human Influenza (ERLI-Net)
The ERLI-Net sub-network of reference laboratories of the European Influenza Surveillance Network carries out virological surveillance of human influenza in the EU/EEA through the EISN timely reporting mechanism and strengthening laboratory capacity for influenza virus detection, antiviral susceptibility testing and typing.
About the network
The main objectives of ERLI-Net are to carry out virological surveillance of human influenza and to ensure that data are shared through the European Influenza Surveillance Network (EISN) reporting mechanisms in a timely manner.
Influenza laboratory quality control
In accordance with the Key Tasks, ERLI-Net laboratories should participate in external quality assurance (EQA) schemes. EQA panels are distributed by both ERLI-Net and the WHO.
WHO global web-based tool for influenza virological surveillance (FluNet)
FluNet is a global web-based tool for influenza virological surveillance. The number of influenza viruses detected by subtype are critical for tracking the movement of viruses globally and interpreting the epidemiological data. The data at country level are publically available and updated weekly. The results are presented in various formats including tables, maps and graphs.
External quality assessment scheme for influenza virus detection, isolation and culture for the European Reference Laboratory Network for Human Influenza, 2013
In September/October 2013, the European Reference Laboratory Network for Human Influenza (ERLI-Net) conducted an external quality assessment (EQA) for the rapid detection of influenza virus, its isolation and culture.
Handbook on tuberculosis laboratory diagnostic methods in the European Union - Updated 2018
This handbook provides network members and other laboratories involved in the diagnosis of tuberculosis, with an agreed list of key diagnostic methods and their protocols in various areas of TB diagnosis.
Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe
Pozo, F., Lina, B., Andrade, H.R., Enouf, V., Kossyvakis, A., Broberg, E., Daniels, R., Lackenby, A., Meijer, A.
Editorial commentary: Critical contribution of laboratories to outbreak response support for middle east respiratory syndrome coronavirus
2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children.
Kissling, E., Valenciano, M., Pozo, F., Vilcu, A.M., Reuss, A., Rizzo, C., Larrauri, A., Horvath, J.K., Brytting, M., Domegan, L., Korczynska, M., Meijer, A., Machado, A., Ivanciuc, A., Visekruna Vucina, V., van der Werf, S., Schweiger, B., Bella, A., Gherasim, A., Ferenczi, A., Zakikhany, K., O'Donnell, J., Paradowska-Stankiewicz, I., Dijkstra, F., Guiomar, R., Lazar, M., Kurecic Filipovic, S., Johansen, K., Moren, A., I-MOVE/I-MOVE+ study team
Aiming for zero tuberculosis transmission in low-burden countries
Marais, B.J., Walker, T.M., Cirillo, D.M., Raviglione, M., Abubakar, I., van der Werf, M.J., Boehme, C., Niemann, S., Castro, K.G., Zumla, A., Sintchenko, V., Crook, D.W.